Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | GBA1 | P04062 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4980028 | 0.81 | MEN1 (0.45) | SIGMAR1KCNH2GBA1TDP1 | |
| SCHEMBL4986011 | 0.78 | SIGMAR1 (0.50) | SIGMAR1KCNH2 | |
| SCHEMBL9827958 | 0.77 | KCNH2 (0.45) | SIGMAR1KCNH2HTR2AHRH1 | |
| SCHEMBL7790878 | 0.76 | AOC3 (0.55) | SIGMAR1KCNH2HTR2AHRH1AOC3 | |
| SCHEMBL4988311 | 0.75 | SIGMAR1 (0.42) | SIGMAR1KCNH2GBA1HTR2AHRH1 | |
| SCHEMBL869237 | 0.74 | SLC2A1 (0.57) | SIGMAR1HTR2AHRH1AOC3 | |
| SCHEMBL13132265 | 0.74 | SLC2A1 (0.57) | SIGMAR1HTR2AHRH1AOC3 | |
| SCHEMBL27287382 | 0.74 | KCNH2 (0.58) | SIGMAR1KCNH2HTR2AHRH1 | |
| SCHEMBL20683723 | 0.74 | KCNH2 (0.48) | SIGMAR1KCNH2AOC3TDP1 | |
| SCHEMBL2295530 | 0.74 | HTR2A (0.64) | KCNH2GBA1HTR2AHRH1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368573-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | BERTINATO PETER | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | APOB, MTPN, CTRB1 | SIGMAR1 279/4885KCNH2 4190/4885GBA1 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.